Background: Patients with chronic liver disease (CLD) have impaired vaccine immunogenicity and an excess risk of severe COVID-19. While variant-adapted COVID-19 mRNA vaccines are recommended for vulnerable individuals. their efficacy in patients with CLD has not been studied. Methods: We present the first evaluation of XBB.